cancer

New cancer therapy extends life for terminally ill dogs — ScienceDaily

Dogs are man’s best friend and dog owners are always embarrassed when their beloved pets get terminally ill. Canine cancer is the leading cause of death in dogs and when they are diagnosed with a late stage or terminal disease, there are often no treatment options available. In a recent study, however, a new form …

New cancer therapy extends life for terminally ill dogs — ScienceDaily Read More »

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy details Category: DNA RNA and cells Posted on Saturday, January 28, 2023 at 6:33 pm Visit: 132 The START-001 study uses a tissue-agnostic biomarker-enriched approach to evaluate …

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells Read More »

First patient injected with new radiotherapy in phase 2b brain cancer trial

The first patient was dosed in a phase 2b clinical trial evaluating rhenium (186Re) obisbemed, a new injectable radiotherapy, for the treatment of recurrent glioblastoma, a type of brain cancer. Researchers conducting the ReSPECT-GBM trial will evaluate the safety, tolerability, distribution and efficacy of rhenium (186Re) obisbemed, according to a press release from Plus Therapeutics, …

First patient injected with new radiotherapy in phase 2b brain cancer trial Read More »

Trial of a new drug in KRAS-mutant lung cancer

A new study has just been launched that will study a new drug, VIC-1911, alone or given in combination with Lumakras (sotorasib) for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to VITRAC Therapeutics, the maker of VIC-1911. VIC-1911 works by inhibiting the amplification or overexpression of the AURKA gene, which previous research …

Trial of a new drug in KRAS-mutant lung cancer Read More »

New combinations promote individualized bladder and prostate cancer care

Investigational combinations, such as androgen deprivation therapy (ADT) plus lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) and androgen receptor (AR) signaling inhibitors in prostate cancer and sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in urothelial carcinoma, may open up increasingly specific treatment options, according to Alicia Morgans, MD, MPH. “During [advances in these fields] it requires continuous learning …

New combinations promote individualized bladder and prostate cancer care Read More »

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer

Zolbetuximab plus mFOLFOX6—a chemotherapy combination commonly used in gastric cancer—significantly prolonged patients’ progression-free survival compared with mFOLFOX6 alone in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction ( GEJ) adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial. The results, presented during the 2023 Gastrointestinal Cancer Symposium, a conference organized …

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer Read More »

New cellular ‘switches’ found to fuel lung cancer growth, resistance to treatment

SCLC cell lines have divergent gene regulatory networks and phenotypes. (A) Hierarchical clustering was performed using 53 SCLC cell lines. Silhouette widths were calculated, which measure the similarity within each group. j, number of clusters; nI, number of samples in each cluster; aveSi, average silhouette width for each cluster. (B) Log fold change (FC) for …

New cellular ‘switches’ found to fuel lung cancer growth, resistance to treatment Read More »

FDA approves fast track designation of new TKK1 therapy for ER+/HER2- advanced breast cancer

The investigational drug, CFI-402257, has earned the FDA’s attention due to promising preclinical results and is now being investigated in a phase 1 study. The FDA granted fast-track designation to CFI-402257 for the treatment of adult patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy, as …

FDA approves fast track designation of new TKK1 therapy for ER+/HER2- advanced breast cancer Read More »

EVQLV and Libera Bio are collaborating to develop and deliver new antibodies for intracellular cancer targets

EVQLV Inc. and Libera Bio SL have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets that represent unmet medical needs. Antibodies can be designed to engage very specific targets along cancer pathways A lots of the best validated intracellular targets for cancer are considered “untreatable” because large …

EVQLV and Libera Bio are collaborating to develop and deliver new antibodies for intracellular cancer targets Read More »

bioAffinity Technologies announces the grant of US patents protecting novel compounds for the specific delivery of cancer treatment

SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for a patent application entitled “Porphyrin compounds and compositions useful for the treatment of cancer” for the targeted delivery of new cancer drugs. A Notice of Allowance is issued after the …

bioAffinity Technologies announces the grant of US patents protecting novel compounds for the specific delivery of cancer treatment Read More »